Venet M, Lepine A, Maarouf A, Biotti D, et al. Control of disease activity with large extended-interval dosing of rituximab/ocrelizumab in highly active pediatric multiple sclerosis. Mult Scler 2024 Jan 2:13524585231223069. doi: 10.1177/13524585231223069.
PMID: 38166437